An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A patient posted that their doctor was strongly against trying semaglutide because they already use Soliqua, a medication that mixes insulin with a GLP-1 drug. They asked whether people with diabetes who are on insulin or other diabetes pills stopped or reduced their insulin after starting a GLP-1 and how they monitored blood sugar. The post reflects a real-world worry: how do new weight-loss/diabetes drugs interact with existing diabetes treatments? Semaglutide is the active ingredient in drugs like Ozempic and Wegovy. It’s a lab-made copy of a natural gut hormone that helps control blood sugar and appetite. In plain terms: it tells your body to release insulin at the right times, slows how fast your stomach empties (which helps you feel full), and nudges your brain to eat less. Doctors prescribe versions of semaglutide either for lowering blood sugar in diabetes or for weight loss, depending on the dose and approved product. The question in the post is mostly practical and comes from experience, not a single new study. Clinical research and prescribing guides show that when people with type 2 diabetes start a GLP-1 drug like semaglutide, they often need their insulin dose adjusted. That’s because GLP-1s lower blood sugar and can boost the effect of insulin. Most formal trials look at groups of patients under medical supervision, not casual self-experimentation, and they find reductions in A1c (a long-run blood sugar measure) and sometimes weight. But individual responses vary. The post isn’t reporting trial results — it’s asking other patients what they did in practice, so the evidence there will be anecdotes, not controlled data. Why this matters is simple: if you’re already taking insulin (or a combination product like Soliqua, which is insulin plus a GLP-1), adding another GLP-1 or increasing diabetes treatment can change how much insulin you need. That affects risk of hypoglycemia (low blood sugar), which can be dangerous. People on insulin who start semaglutide may be able to lower their insulin dose, but they should do it with guidance. Endocrinologists and diabetes care teams typically recommend closer blood-sugar monitoring in the first weeks and stepwise dose changes, not abrupt stops. There are important caveats. Don’t stop or change insulin on your own — low blood sugar can be serious. Doctors worry about overlapping therapies like two GLP-1 drugs or combining meds without clear benefit. Side effects from GLP-1s include nausea, vomiting, and sometimes more serious but rarer risks that your doctor should discuss. Also, insurance coverage and official approvals matter: some combinations or doses are approved; others are off-label. We don’t have a one-size-fits-all answer — decisions depend on the person’s current control, type of diabetes, and medical history. Bottom line: GLP-1 drugs like semaglutide can reduce the need for insulin for some people, but any change should be done under medical supervision with more frequent blood-sugar checks.
Source: r/Semaglutide